Hitomi Sumiyoshi-Okuma

13PUBLICATIONS
104CO-AUTHORS
Predictive and prognostic markersAutoimmunityMolecular targetsPharmaceutical delivery technologiesMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 29, 2026
Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis.

|Apr 14, 2026
Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.

Paul G Kemps, Jennifer L Picarsic, Sébastien Héritier

|Feb 04, 2026
Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project.

Hitomi Sumiyoshi Okuma, Kenji Tsuchihashi, Eishi Baba

|Jan 08, 2026
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Ferran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel

|Nov 22, 2024
Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline.

Akihiro Hirakawa, Takashi Asakawa, Kota Tokushige

|Aug 14, 2024
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

Rui Kitadai, Tatsunori Shimoi, Shu Yazaki

Pageof 3

Frequent Collaborators

6 joint publications

Kan Yonemori

4 joint publications

Tatsunori Shimoi

4 joint publications

Kenichi Nakamura

3 joint publications

Kazuki Sudo